Rut Porta
Institut Català d'Oncologia · 37 works · 8,749 citations · h-index 13
Top works
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
- Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
- FGFR a promising druggable target in cancer: Molecular biology and new drugs
- Host and Direct Antitumor Effects and Profound Reduction in Tumor Metastasis with Selective EP4 Receptor Antagonism
- Fatty acid metabolism in breast cancer cells: differential inhibitory effects of epigallocatechin gallate (EGCG) and C75
- Response of brain metastasis from lung cancer patients to an oral nutraceutical product containing silibinin
- Inhibition of Epidermal Growth Factor Receptor Signaling Elevates 15-Hydroxyprostaglandin Dehydrogenase in Non–Small-Cell Lung Cancer
- Successful empirical erlotinib treatment of a mechanically ventilated patient newly diagnosed with metastatic lung adenocarcinoma
- Neoadjuvant Chemoradiotherapy Treatment for a Classic Biphasic Pulmonary Blastoma with High PD-L1 Expression.
- Assessment of ALK Status by FISH on 1000 Spanish Non-Small Cell Lung Cancer Patients
- Predictive biomarkers in the management of EGFR mutant lung cancer
- Fatty acid synthase expression is strongly related to menopause in early-stage breast cancer patients
- Association of p53 mutations with progression-free survival (PFS) and overall survival (OS) in EGFR-mutated non-small cell lung cancer (NSCLC) patients (p) treated with erlotinib.
- Skin toxicity associated with outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) with EGFR mutations in the EURTAC study.
- Polycaprolactone Electrospun Scaffolds Produce an Enrichment of Lung Cancer Stem Cells in Sensitive and Resistant EGFRm Lung Adenocarcinoma
- Sintasa de ácidos grasos como nueva diana antitumoral
- Estrés oxidativo en pacientes con cáncer: dos caras de una misma moneda
- AZ12756122, a novel fatty acid synthase inhibitor, decreases resistance features in EGFR-TKI resistant EGFR-mutated NSCLC cell models
- Paraneoplastic Limbic Encephalitis in a Male with Squamous Cell Carcinoma of the Lung